C4 Therapeutics, Inc. (CCCC) stock
CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3019% above fair value
$2.77−0.12 (-4.15%)
Close on Nov 12, 2026Market cap $340.78MP/E –Yield –
C4 Therapeutics statistics
77 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Last ex-dividend date
- No dividends
- Fundamentals through
- Sep 30, 2026
- Share price as of
- Nov 11, 2026
Valuation ratiosIndustry
- P/TBV Ratio
- 1.56
- 2.38
Enterprise valuationIndustry
- EV / Sales
- 2.50
- 2.65
Share statisticsIndustry
- Shares Change (YoY)
- 78.9%
- 10.9%
- Shares Change (QoQ)
- 6.84%
- 0.48%
- Float
- 120M
- 49M
- Shares Held by Insiders
- 2.77%
- 12.1%
- Shares Held by Institutions
- 95.6%
- 56.4%
Short sellingIndustry
- Short Interest
- 47M
- –
- Short Interest Change
- 9.03%
- -0.80%
- Short % of Float
- 38.9%
- 9.06%
- Short % of Shares Outstanding
- 37.9%
- 6.30%
- Days to Cover
- 15.14
- 5.15
Stock price statisticsIndustry
- 52-Week High
- $5.17
- –
- 52-Week Low
- $1.69
- –
- 20-Day Moving Average
- $3.09
- –
- 50-Day Moving Average
- $3.17
- –
- 200-Day Moving Average
- $3.24
- –
- Average True Range (14)
- $0.23
- –
- Price Change (1 Week)
- -7.37%
- -0.58%
- Price Change (1 Month)
- 3.96%
- -0.28%
- Price Change (3 Months)
- -29.2%
- -17.1%
- Price Change (6 Months)
- -21.5%
- -20.1%
- Price Change (YTD)
- 51.3%
- -20.1%
- Price Change (1 Year)
- 23.5%
- -19.3%
- Price Change (3 Years)
- 73.1%
- -22.2%
- Price Change (5 Years)
- -93.1%
- -76.4%
- Average Volume (10 Days)
- 3M
- –
- Average Volume (20 Days)
- 3M
- –
- Average Volume (90 Days)
- 3M
- –
- Relative Volume
- 0.82
- 0.73
- Relative Strength Index (14)
- 42.5
- 47.7
- Volatility (1 Year)
- 80.9%
- 80.2%
- Beta (5 Years)
- 2.52
- 1.08
MarginsIndustry
- EBITDA Margin
- -311.4%
- -27.7%
- FCF Margin
- -247.1%
- -8.85%
Returns on capitalIndustry
- Return on Equity (ROE)
- -47.6%
- -51.3%
- Return on Assets (ROA)
- -30.5%
- -40.7%
- Return on Capital Employed (ROCE)
- -35.1%
- -38.1%
Financial positionIndustry
- Current Ratio
- 5.17
- 3.30
- Quick Ratio
- 6.66
- 2.40
GrowthIndustry
- Revenue Growth (YoY)
- 7.20%
- 7.26%
- Revenue Growth (3Y CAGR)
- 4.95%
- 2.25%
EfficiencyIndustry
- Asset Turnover
- 0.11
- 0.40
- Revenue Per Employee
- $310.36K
- $429.38K
- Profits Per Employee
- -$875.89K
- -$683.67K
- Employee Count
- 104
- 75
- WACC
- 17.4%
- 10.1%
Income statement (TTM)Industry
Balance sheetIndustry
- Net Cash (Debt)
- $274.70M
- $16.56M
- Net Cash Per Share
- $2.23
- $0.71
- Equity (Book Value)
- $228.17M
- $52.23M
- Book Value Per Share
- $1.85
- $1.50
- Tangible Book Value
- $228.17M
- $26.10M
- Working Capital
- $173.04M
- $78.41M
Cash flow (TTM)Industry
- Capital Expenditures
- -$112.00K
- -$944.00K
- FCF Per Share
- -$0.65
- -$0.42
Dividends and yieldsIndustry
- Earnings Yield
- -25.6%
- -20.1%
- FCF Yield
- -22.4%
- -9.14%
- Buyback Yield
- 0.07%
- -0.69%
- Shareholder Yield
- 0.07%
- 0.00%
Taxes and interestIndustry
- Income Tax
- $121.00K
- $74.00K
Scores and fair valueIndustry
- Altman Z-Score
- -1.65
- 0.31
- Piotroski F-Score
- 4
- 4
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | CCCC | S&P 500 | Difference | CCCC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -9.5% | -2.7% | −6.8 pts | ||
| 3 months | -29.0% | -1.7% | −27.2 pts | ||
| Year to date | +45.0% | +11.9% | +33.1 pts | ||
| 1 year | +11.7% | +12.0% | −0.3 pts | ||
| 3 years | +61.0% | +78.2% | −17.1 pts | +17.2% | +21.2% |
| 5 years | -93.4% | +73.2% | −166.6 pts | -41.9% | +11.6% |
Short interest
Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.
47M CCCC shares were sold short on Oct 30, 2026, up 9.0% from the previous report, or 38.94% of the shares available to trade. At recent volumes it would take 15.1 days to buy them back. Over the last 20 sessions, 53.8% of the volume reported to FINRA was short selling.
| Settlement date | Shares short | Change | Avg. daily volume | Days to cover |
|---|---|---|---|---|
| Oct 30, 2026 | 46,580,600 | +9.0% | 3,076,710 | 15.1 |
| Oct 15, 2026 | 42,722,018 | +5.8% | 2,520,136 | 16.9 |
| Sep 30, 2026 | 40,395,665 | +0.5% | 2,289,003 | 17.6 |
| Sep 15, 2026 | 40,189,287 | +7.4% | 1,771,956 | 22.7 |
| Aug 31, 2026 | 37,413,259 | +9.9% | 2,235,382 | 16.7 |
| Aug 14, 2026 | 34,048,321 | +11.9% | 2,444,712 | 13.9 |
| Jul 31, 2026 | 30,427,514 | +27.8% | 2,735,917 | 11.1 |
| Jul 15, 2026 | 23,815,010 | -4.7% | 3,579,482 | 6.7 |
| Jun 30, 2026 | 24,997,175 | +12.4% | 4,757,093 | 5.3 |
| Jun 15, 2026 | 22,246,308 | +2.8% | 2,336,354 | 9.5 |
| May 29, 2026 | 21,650,001 | +1.9% | 2,295,870 | 9.4 |
| May 15, 2026 | 21,254,462 | +0.9% | 3,661,085 | 5.8 |
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.
See a number that looks wrong?